IN2014MU00303A - - Google Patents
Download PDFInfo
- Publication number
- IN2014MU00303A IN2014MU00303A IN303MU2014A IN2014MU00303A IN 2014MU00303 A IN2014MU00303 A IN 2014MU00303A IN 303MU2014 A IN303MU2014 A IN 303MU2014A IN 2014MU00303 A IN2014MU00303 A IN 2014MU00303A
- Authority
- IN
- India
- Prior art keywords
- pharmaceutical composition
- relates
- abiraterone
- abstract
- preparing
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- GZOSMCIZMLWJML-VJLLXTKPSA-N abiraterone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CC[C@H](O)CC3=CC2)C)CC[C@@]11C)C=C1C1=CC=CN=C1 GZOSMCIZMLWJML-VJLLXTKPSA-N 0.000 abstract 1
- 229960000853 abiraterone Drugs 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/GB2015/050175 WO2015114314A1 (en) | 2014-01-28 | 2015-01-27 | Pharmaceutical composition comprising abiraterone |
| IN303MU2014 IN2014MU00303A (enExample) | 2014-01-28 | 2015-01-27 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN303MU2014 IN2014MU00303A (enExample) | 2014-01-28 | 2015-01-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MU00303A true IN2014MU00303A (enExample) | 2015-09-11 |
Family
ID=52462940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN303MU2014 IN2014MU00303A (enExample) | 2014-01-28 | 2015-01-27 |
Country Status (2)
| Country | Link |
|---|---|
| IN (1) | IN2014MU00303A (enExample) |
| WO (1) | WO2015114314A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3824908A1 (en) | 2015-04-10 | 2021-05-26 | Capsugel Belgium NV | Abiraterone acetate lipid formulations |
| EP3500310A1 (en) | 2016-08-20 | 2019-06-26 | FTF Pharma Private Limited | Pharmaceutical composition comprising an androgen receptor inhibitor |
| SI3526202T1 (sl) | 2016-10-11 | 2025-04-30 | Arvinas Operations, Inc. | Spojine in postopki za ciljno razgradnjo androgenskih receptorjev |
| US11865215B2 (en) | 2018-04-26 | 2024-01-09 | Synthon B.V. | Tablet compositions comprising abiraterone acetate |
| EP3897585A1 (en) * | 2018-12-20 | 2021-10-27 | Pharmaceutical Oriented Services Ltd | Dosage form containing abiraterone acetate |
| EP3999040A4 (en) * | 2019-07-15 | 2023-07-19 | Shilpa Medicare Limited | DISPERSABLE TABLETS OF ABIRATERONACETATE |
| US20210113557A1 (en) * | 2019-10-22 | 2021-04-22 | Arvinas Operations, Inc. | Methods of treating prostate cancer |
| CN113384532B (zh) * | 2020-03-14 | 2024-03-29 | 鲁南制药集团股份有限公司 | 一种cyp17抑制剂固体分散体及其制备方法 |
| CN115996918A (zh) | 2020-05-09 | 2023-04-21 | 阿尔维纳斯运营股份有限公司 | 制造双官能团化合物的方法、双官能团化合物的超纯形式以及包括所述双官能团化合物的剂型 |
| EP3944860A1 (en) * | 2020-07-30 | 2022-02-02 | Galenicum Health S.L.U. | Abiraterone for use in a method of treating cancer |
| CN115475172B (zh) * | 2021-06-15 | 2023-12-01 | 北京泰德制药股份有限公司 | 一种含有阿比特龙或其药用盐的药用组合物 |
| AU2024392985A1 (en) | 2023-12-08 | 2026-06-04 | Arvinas Operations, Inc. | Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20140166A1 (es) * | 2010-10-01 | 2014-02-17 | Cipla Ltd | Composicion farmaceutica que comprende deferasirox |
| GB201207886D0 (en) * | 2012-05-04 | 2012-06-20 | Jagotec Ag | Improvements in or relating to organic compounds |
| WO2014009436A1 (en) * | 2012-07-11 | 2014-01-16 | Sandoz Ag | Nanosuspension of abiraterone acetate |
| TWI686212B (zh) * | 2013-03-15 | 2020-03-01 | 阿聯商太陽法瑪全球有限公司 | 醋酸阿比特龍配方 |
-
2015
- 2015-01-27 WO PCT/GB2015/050175 patent/WO2015114314A1/en not_active Ceased
- 2015-01-27 IN IN303MU2014 patent/IN2014MU00303A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015114314A1 (en) | 2015-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202004557B (en) | Modulatory polynucleotides | |
| PL3616720T3 (pl) | Kompozycja farmaceutyczna do leczenia nowotworu | |
| MX2023010042A (es) | Polinucleotidos moduladores. | |
| IL290149A (en) | Combined treatment for cancer | |
| TW201613901A (en) | New compounds | |
| ZA201905902B (en) | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | |
| GB2541571A (en) | Pharmaceutical compositions | |
| NZ725480A (en) | Anti-ptk7 antibody-drug conjugates | |
| LT3473263T (lt) | Kombinuoti preparatai, skirti vėžio gydymui | |
| PH12016501830A1 (en) | Inhibitors of c5a for the treatment of viral pneumonia | |
| MX2017002489A (es) | Agentes terapeuticos humanos. | |
| PH12016501841A1 (en) | Immunosuppressant formulation | |
| PH12017500239A1 (en) | Abiraterone acetate formulation and methods of use | |
| WO2015123449A3 (en) | Compositions and methods of using microrna inhibitors | |
| MX2018003563A (es) | Nuevos compuestos. | |
| PH12017500853B1 (en) | Cd44v6-derived cyclic peptides for treating cancers and angionesesis related diseases | |
| IL275525A (en) | A pharmaceutical preparation for the treatment of cancer | |
| PH12017500602A1 (en) | Methods for treating ocular conditions | |
| HK1254231A1 (zh) | 米托-和厚朴酚化合物及其合成方法和用途 | |
| IL266486A (en) | Pharmaceutical preparations and methods for cancer treatment | |
| MX382092B (es) | Compuestos heterocíclicos para el tratamiento de enfermedades. | |
| MX2020000135A (es) | Nuevos compuestos de quinolinona. | |
| IN2014MU00495A (enExample) | ||
| GB201719584D0 (en) | Pharmaceutical compositions for the treatment of cancer | |
| PT3580211T (pt) | 2-heteroaril-3-oxo-2,3-di-hidropiridazina-4-carboxamidas para o tratamento de cancro |